Esperion Therapeutics, Inc. (LON:0IIM)
1.367
-0.041 (-2.91%)
At close: Aug 1, 2025
Esperion Therapeutics Employees
Esperion Therapeutics had 304 employees as of December 31, 2024. The number of employees increased by 64 or 26.67% compared to the previous year.
Employees
304
Change (1Y)
64
Growth (1Y)
26.67%
Revenue / Employee
$660,881
Profits / Employee
-$390,106
Market Cap
209.48M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 304 | 64 | 26.67% |
Dec 31, 2023 | 240 | 41 | 20.60% |
Dec 31, 2022 | 199 | -19 | -8.72% |
Dec 31, 2021 | 218 | -261 | -54.49% |
Dec 31, 2020 | 479 | 286 | 148.19% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 94,300 |
GSK plc | 68,629 |
Haleon | 24,561 |
Smith & Nephew | 17,349 |
ConvaTec Group | 10,489 |
Hikma Pharmaceuticals | 9,500 |
HUTCHMED (China) | 1,811 |
Oxford Nanopore Technologies | 1,382 |
Esperion Therapeutics News
- 8 days ago - Esperion Therapeutics soars amid vague takeover speculation - Seeking Alpha
- 11 days ago - Esperion to Report Second Quarter 2025 Financial Results on August 5 - GlobeNewsWire
- 4 weeks ago - Esperion Appoints Craig Thompson to Board of Directors - GlobeNewsWire
- 7 weeks ago - Can The Promise Of Profitability And Pipelines Sustain A Recovery For Esperion Therapeutics? - Seeking Alpha
- 2 months ago - Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040 - GlobeNewsWire
- 3 months ago - Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference - GlobeNewsWire
- 3 months ago - Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - HLS Therapeutics Announces Q1 2025 Financial Results - Benzinga